MDT-AP-0756
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 30
- os_event
- false
- age_years
- 8
- sex
- M
- new_clusters
- C2
- umap1_2d
- 2.352926241
- umap2_2d
- 1.250326509
- umap1_3d
- -0.451453809
- umap2_3d
- -2.70993798
- umap3_3d
- -1.994852725
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.570
- MYC_TARGETS_V1+0.510
- OXIDATIVE_PHOSPHORYLATION+0.410
- DNA_REPAIR+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.290
- E2F_TARGETS+0.140
- G2M_CHECKPOINT+0.140
- WNT_BETA_CATENIN_SIGNALING+0.140
- GLYCOLYSIS+0.130
- ADIPOGENESIS+0.110
Top 10 suppressed
- INTERFERON_GAMMA_RESPONSE-0.550
- INTERFERON_ALPHA_RESPONSE-0.540
- INFLAMMATORY_RESPONSE-0.520
- ALLOGRAFT_REJECTION-0.480
- COMPLEMENT-0.410
- IL6_JAK_STAT3_SIGNALING-0.410
- BILE_ACID_METABOLISM-0.360
- KRAS_SIGNALING_UP-0.350
- APICAL_SURFACE-0.330
- TNFA_SIGNALING_VIA_NFKB-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2388 | Med | Medulloblastoma | 0.916 |
| 2 | SRR10899994 | — | — | 0.914 |
| 3 | SRR8518345 | — | E | 0.905 |
| 4 | MDT-AP-0575 | Med | Medulloblastoma | 0.898 |
| 5 | MDT-AP-0421 | Med | Medulloblastoma | 0.896 |
| 6 | ERR2598212 | fetal | fetal | 0.894 |
| 7 | SRR6013533 | — | cohortSQ2 | 0.890 |
| 8 | TCGA-UF-A71A-06A-11R-A39I-07 | — | — | 0.889 |
| 9 | 20120209.TNBC | — | E | 0.887 |
| 10 | SAMN03290931 | — | — | 0.886 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.570 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.510 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.410 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.290 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.140 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.140 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.140 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.130 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.110 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.100 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.070 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.070 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.050 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.030 | Cobimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.020 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.020 | Inavolisib | — uncovered |
| PEROXISOME | 0.010 | Idelalisib | — uncovered |